This article looks at the challenges facing the German medical care system and looks at past and future reforms in the German pharmaceutical market, focusing on: • The Act for the restructuring of the drug market (Gesetz zur Neuordnung des Arzneimittelmarktes) (AMNOG). • The early benefit assessment. • The reference price system. • Negotiations between pharmaceutical companies and the statutory health insurance (Gesetzliche Krankenversicherung) (SHI). • Manufacturer's statutory rebates for pharmaceuticals.

This article is part of the PLC multi-jurisdictional guide to Life Sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifescienceshandbook.